Globus Medical (NYSE:GMED) has shifted its Excelsius surgical robotics platform from outright sales to leasing and rental ...

A decision on the resubmitted application is expected within 60 days of the FDA’s receipt of it, the company said.

The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of ...

Qure N.V. hinges on the AMT-130 FDA outcome; a Type B meeting may help, but Phase 3 is likely. Click for this updated look at ...

Natera gets a buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue ...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best cheap stocks under $10 to buy in June. On May 4, ADMA Biologics received ...

Vormatrigine was generally well-tolerated, with adverse event-related discontinuations below 10%, the firm said. ・Praxis said it is pausing enrollment in the POWER2 study to reassess the overall ...

A major catalyst window opens for this biopharma stock with Q1 earnings due on May 6, and two key FDA decisions in May and July.

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks ...

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer ...

Eli Lilly stock (LLY) popped by more than 5% on Wednesday after the Food and Drug Administration (FDA) approved the company's new weight-loss pill that Eli Lilly says can be taken "any time of day ...